Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hypercalcaemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Hypercalcaemia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2009-009756-21 Sponsor Protocol Number: 20070315 Start Date*: 2009-10-26
    Sponsor Name:Amgen Inc
    Full Title: A Single-arm, Multicenter, Proof-of-concept Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects with Elevated Serum Calcium Despite Recent Treatment with IV Bisphosphonates.
    Medical condition: Hypercalcemia of malignancy (HCM)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10014698 - Endocrine disorders 10020588 Hypercalcemia of malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000573-29 Sponsor Protocol Number: 20062007 Start Date*: 2009-10-16
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Using Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients With Autonomous Hyperparathyroid...
    Medical condition: Renal transplant recipients with hypercalcemia and autonomous hyperparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020587 Hypercalcemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Completed) ES (Completed) IT (Completed) AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001376-12 Sponsor Protocol Number: BISMARK 2005 Start Date*: 2005-08-19
    Sponsor Name:University of Sheffield
    Full Title: Cost-effective use of BISphonphonates in metastatic bone disease - a comparison of bone MARKer directed zoledronic acid therapy to a standard schedule.
    Medical condition: Advanced breast cancer with bone metastases
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002583-27 Sponsor Protocol Number: MCI-196-E15 Start Date*: 2013-07-11
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000608-42 Sponsor Protocol Number: ISRCTN79831382/NovartisCZOL446G2408 Start Date*: 2004-11-19
    Sponsor Name:University of Sheffield
    Full Title: A randomised study to determine whether zoledronic acid adds to the benefits of chemotherapy and/or hormone therapy in the treatment of women with breast cancer. –AZURE STUDY–
    Medical condition: Stage II/III primary breast cancer, with T stage ≥ T1
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001816-56 Sponsor Protocol Number: HUM 05-064 Start Date*: 2006-05-11
    Sponsor Name:Rigshospitalet
    Full Title: Can PET scan be used to assess disease activity in patients with sarcoidosis during treatment with adalimumab (Humira)?
    Medical condition: sarcoidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005008-32 Sponsor Protocol Number: ICORG13-17 Start Date*: 2014-07-16
    Sponsor Name:Cancer Trials Ireland
    Full Title: A phase II Study of the Efficacy and Safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma
    Medical condition: Newly diagnosed multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000073-24 Sponsor Protocol Number: CTRIAL-IE-19-33 Start Date*: 2020-09-07
    Sponsor Name:Cancer Trials Ireland
    Full Title: Paricalcitol Trial: Phase II, Open label clinical trial of Paricalcitol in combination with Gemcitabine/ Nab-Paclitaxel therapy in advanced pancreatic cancer.
    Medical condition: Advanced pancreatic cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    21.0 100000004864 10033607 Pancreatic cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001258-25 Sponsor Protocol Number: HM20/123197 Start Date*: 2020-05-14
    Sponsor Name:University of Leeds
    Full Title: Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell trans...
    Medical condition: Newly diagnosed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-002582-35 Sponsor Protocol Number: MCI-196-E16 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000649-36 Sponsor Protocol Number: QuiReDex Start Date*: 2007-07-23
    Sponsor Name:Fundación PETHEMA
    Full Title: Estudio nacional, multicéntrico, aleatorizado, abierto, fase III de Revlimid (Lenalidomida) más Dexametasona (ReDex) versus observación en pacientes con Mieloma Múltiple (MM) quiescente (MM smolder...
    Medical condition: Mieloma múltiple quiescente con alto riesgo de progresión a mieloma múltiple sintomático
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002581-12 Sponsor Protocol Number: MCI-196-E14 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy with a ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006064-32 Sponsor Protocol Number: FP-005-IM Start Date*: 2008-02-21
    Sponsor Name:Nycomed Danmark Aps
    Full Title: Ensayo clínico de fase IV, internacional, multicéntrico, aleatorizado, doble ciego, doble enmascaramiento, de grupos paralelos, de 24 semanas, que estudia los cambios en el dolor lumbar relacionado...
    Medical condition: Primary Postmenopausal Osteoporosis Osteoporosis postmenopáusica primaria
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) FR (Completed) DE (Completed) IT (Completed) GB (Prematurely Ended) IE (Completed) GR (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003902-27 Sponsor Protocol Number: 26866138MMY2031 Start Date*: 2006-02-13
    Sponsor Name:ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH
    Full Title: Clinical trial on induction of remission with bortezomib (Vel), cyclophosphamide (C) and dexamethasone (D) in patients until the age of 60 with untreated multiple myeloma and planned high dosage ch...
    Medical condition: Untreated patients with cytologically and/or histologically established multiple myeloma (Durie and Salmon stage II or III) requiring treatment with measurable myeloma protein in the blood or urine.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004937-16 Sponsor Protocol Number: THA PH INT 2005 CL 001 Start Date*: 2006-02-17
    Sponsor Name:Celgene International Sarl
    Full Title: Randomised, Controlled, Open-Label, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma
    Medical condition: Multiple myeloma (MM) is a malignant, lymphoproliferative disease of the B-cell system. The incidence is approximately 4 per 100,000 and it is age-dependent, with an increase in incidence of approx...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed) SK (Completed) PT (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002089-37 Sponsor Protocol Number: EMN18 Start Date*: 2019-03-04
    Sponsor Name:EUROPEAN MYELOMA NETWORK
    Full Title: A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAME...
    Medical condition: YOUNG PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM) TO THE DIAGNOSIS ELIGIBLE TO THE AUTOLOGOUS TRANSMISSION OF STEM CELLS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing) GR (Ongoing) CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001183-19 Sponsor Protocol Number: GEM-CLARIDEX Start Date*: 2015-09-30
    Sponsor Name:Fundación PETHEMA
    Full Title: Lenalidomide and dexamethasone (Ld) versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as initial therapy in Multiple Myeloma.
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005104-25 Sponsor Protocol Number: INV500 Start Date*: 2018-01-02
    Sponsor Name:Nova BioPharma Limited
    Full Title: Relative bioavailability and comparative pharmacokinetics of 13-CRA oral liquid and extracted capsule formulations: a randomised, open label, multi-dose, cross-over clinical trial in patients requi...
    Medical condition: Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    20.0 10029205 - Nervous system disorders 10029212 Nervous system neoplasms malignant NEC HLT
    20.0 10029205 - Nervous system disorders 10029211 Nervous system neoplasms malignant and unspecified NEC HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022012-40 Sponsor Protocol Number: PA-CL-05B Start Date*: 2011-02-21
    Sponsor Name:Vifor (International) Inc.
    Full Title: An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre Phase 3 Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21 compared with Sevelamer Carbonate in D...
    Medical condition: Control of hyperphosphataemia in patients with chronic kidney disease on dialysis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    15.0 10027433 - Metabolism and nutrition disorders 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) LV (Completed) LT (Completed) SE (Completed) AT (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-004130-11 Sponsor Protocol Number: GEM21menos65 Start Date*: 2022-08-23
    Sponsor Name:FUNDACION PETHEMA
    Full Title: GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D
    Medical condition: Newly-diagnosed multiple myeloma (NDMM) patients who are candidates for Autologous Stem Cell Transplant (ASCT).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10028229 Multiple myelomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA